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osting by EAbstract Purpose: To evaluate the efﬁcacy of the concomitant administration of antiglaucoma
medications namely timolol 0.1% gel in cases with myopic regression after myopic laser in situ ker-
atomileusis (LASIK).
Design: Prospective observational clinical trial.
Subjects and methods: Ninty ﬁve eyes of 75 patients were included in this study prospectively. The
mean myopic regression was 1.29 ± 0.83 diopters (range 0.5 to 4.62) after myopic LASIK.
The eyes were divided into two groups: 50 eyes administrated timolol 0.1% gel once daily for
12 months (treated group), and 45 eyes were age matched (control group). We assessed the amounts
of myopic regression in terms of changes in the refraction (spherical equivalent and astigmatism),
intraocular pressure (IOP), pachymetry and the refractive power of the cornea measurements for all
participants.
Results: The refractive error and visual acuity were similar between the two groups at baseline. The
treated group had an improvement in spherical equivalent signiﬁcantly from 1.29 ± 0.83 to
0.94 ± 1.07 diopters (P= 0.012). Astigmatism was changed from 0.94 ± 0.53 to
0.86 ± 0.60 diopters but this change was not statistically signiﬁcant (P= 0.20). The IOP was
decreased signiﬁcantly from 12.6 ± 1.9 to 9.0 ± 1.1 mm Hg (P< 0.001). Central corneal thicknessmed consent and followed the
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82 H.E. El-Awady et al.was changed from 425.6 ± 19.86 to 429 ± 18.1 lm but not statistically signiﬁcant (P= 0.56). The
central corneal power decreased signiﬁcantly from 37.2 ± 1.8 to 36.4 ± 1.3 diopters (P< 0.05).
Conclusion: Timolol 0.1% gel was effective for reduction and improvement of myopic regression
especially the spherical errors after myopic LASIK.
ª 2010 King Saud University. All rights reserved.1. Introduction
Excimer laser surgery is widely accepted as a predictable and
effective refractive surgical procedure for the correction of
myopia. However, myopic regression of the initial surgical ef-
fect can affect the predictability, efﬁciency, and long-term sta-
bility of refractive surgery, leading to deterioration in visual
performance. It is widely known that some regression does oc-
cur not only after photorefractive keratectomy (PRK) but also
after laser in situ keratomileusis (LASIK) (Lohmann and
Guell, 1998; Magallanes et al., 2001).
Nevertheless, the mechanism for myopic regression is
complicated and is not fully understood. Some authors found
that there was a signiﬁcant correlation between forward shift
of the cornea and the amount of myopic regression in a study
of 65 eyes undergoing PRK, indicating that forward shift of
the cornea can be one of the factors responsible for regres-
sion after excimer laser surgery (Miyata et al., 2002; Kamiya
and Oshika, 2003). In addition, there had been case reports
of transient keratectasia associated with marked elevation
of intraocular pressure (IOP), suggesting that increases in
the internal pressure may have expanded and distended the
cornea, leading to anterior protrusion (Toshino et al., 2005;
Hiatt et al., 2005).
In the last few years, it has also been reported that the pre-
operative IOP was signiﬁcantly higher in regressive eyes than
in non-regressive eyes, whereas there was no signiﬁcant differ-
ence of central corneal thickness between regressive and non-
regressive eyes after LASIK (Qi et al., 2006). These results
indicated that lowering the IOP may be an effective treatment
for refractive regression after keratorefractive surgery.
Timolol 0.1% eye gel (Nyolol gel, Novartis Ophthalmic,
Switzerland) is a non-selective B-blocker with carbomer and
polyvinyl alcohol. It provides ocular comfort and lubrication
also increased retinal and optic nerve perfusion. Its muco-
adhesive hydrogel leads to longer precorneal retention time
hence its use once daily. It reduces IOP by decreasing aqueous
humor production. The purpose of the current study was to
investigate the efﬁcacy of timolol 0.1% gel on the correction
of myopic regression after myopic LASIK.
2. Subjects and methods
This prospective study was conducted on 95 eyes of 75 pa-
tients (40 male and 35 female). The mean age of included pa-
tients was 29.16 ± 4.7 years (range 19–40 years) with myopic
regression of 1.29 ± 0.83 (range 0.5 to 4.62 diopters)
after myopic LASIK. Twenty patients had bilateral and 55
had unilateral LASIK. Informed consents were obtained
from all patients after explaining the nature and possible out-
comes of the study. The study protocol was conducted in
accordance with the ethical principles outlined in the Declara-
tion of Helsinki.The eyes were divided into two groups: 50 eyes adminis-
trated timolol 0.1% gel once daily for 12 months (treated
group), and 45 eyes were age matched (control group).
Inclusion criteria for LASIK were: age of patients 19 years
or more, patients not wearing contact lens 4 weeks before the
surgery, normal peripheral retina, no glaucoma, and stable
refractive error at least 12 months before surgery. Exclusion
criteria were: eyes with central islands, active inﬂammation,
Schirmer test less than 5.0 mm, presence of corneal pathology
(evidence of keratoconus or keratoconus suspect as evidenced
by corneal topography), calculated post-operative corneal
residual stromal bed thickness less than 250 lm, and history
of ocular trauma.
LASIK was performed with the Schwind Esiris excimer la-
ser system using an average ﬂuency of 650 mJ/cm2 with a rep-
etition rate of 200 Hz and pulse duration of 8 ns. Moria M2
single use Microkeratome (Moria, Georgres Besse, Antony,
France) was used for creating a hinged corneal ﬂap of
120 lm in thickness. In all eyes, the pre-operative manifest
spherical equivalent refraction was selected as the target myo-
pic correction.
All patients involved in the study subjected to the following
ophthalmic examinations: uncorrected distant visual acuity
(UDVA), corrected distant visual acuity (CDVA), IOP mea-
surement with a handheld applanation tonometer (Perkins,
Edinbrugh, Scotland), Schirmer test, central corneal pachyme-
try (Nidek Up-1000, Japan), and corneal topography (Optikon
Keratron, Scout, Germany). The refractive power of the total
cornea was averaged within a central zone of 3 mm diameter.
All the measurements were performed at the same time of
day to decrease the effect of the diurnal curve.
Patient satisfaction and optical symptoms surveys were
obtained to document glare, halos, double vision, ghosting,
and disturbance of night vision. These surveys were recorded
at each follow-up visits. The patients’ comments divided into
three categories: satisﬁed, moderate satisﬁed, and dissatisﬁed.
Dissatisﬁed patients were those who reported comments of
no improvement, blurring of vision, and or reporting optical
symptoms.
3. Follow-up
Treated and control patients were examined at the pre-opera-
tive and pos-operative visits (ﬁrst day, ﬁrst week, ﬁrst month,
3 months, 6 months, and 12 months), patients were reviewed
with assessment of uncorrected and corrected distant visual
acuity, intraocular pressure measurement, Schirmer test, cor-
neal topography, and corneal pachymetry.
3.1. Statistical analysis
Statistical analysis was performed using SPSS version 15.
Values were presented as mean ± standard deviation (SD).
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Figure 1 UDVA before and 12 months after treatment.
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used to evaluate the signiﬁcance of difference. The Wilcoxon
single-rank test was used to compare the pre-treatment and
post-treatment. P-value less than 0.05 was considered to be sta-
tistically signiﬁcant.
4. Results
All 95 eyes were followed for 12 months. Table 1 summarizes
the demographic and clinical proﬁles of the patients. Average
age of patients was 29.16 ± 4.7 years (range 19–40 years). The
mean spherical equivalent (SE) before LASIK was 12.52 ±
3.37 diopters, the mean astigmatism before LASIK was
2.11 ± 1.5 diopters, and the mean corneal thickness before
LASIK was 551.48 ± 20.1 diopters.
Table 2 shows the visual and refractive outcomes in the
treated and control groups. The mean UDVA was improved
signiﬁcantly from 0.31 ± 0.11 before treatment to 0.44 ±
0.21 after treatment (P< 0.001) (Fig. 1). Mean CDVA did
not change signiﬁcantly from 0.65 ± 0.11 before treatment
to 0.66 ± 0.08 after treatment (P= 0.39) (Fig. 2).
The mean spherical equivalent improved signiﬁcantly from
1.29 ± 0.83 to 0.94 ± 1.07 diopters 12 months after treat-
ment (P= 0.012) (Fig. 3). Forty ﬁve (47.3%) and 25 (26.3%)
of 95 eyes showed improved of more than 0.5 and 0.25 diop-
ters, respectively.
However, the mean astigmatism was changed from
0.94 ± 0.53 to 0.86 ± 0.60 diopters but the difference
was not signiﬁcant (P= 0.204) (Fig. 4). The mean IOPTable 1 Demographic data and clinical parameters of the
studied patients.
No. of patients 75
No. of eyes 95
Male/female ratio 40/35
Mean age (years) 29.16 ± 4.7
Mean pre-LASIK spherical equivalent (diopters) 12.52 ± 3.37
Pre-LASIK astigmatism (diopters) 2.11 ± 1.15
Pre-LASIK corneal thickness (lm) 551.48 ± 20.1
Table 2 Visual and refractive outcomes in the studied eyes.
Outcomes Group Baseline 12 Months
Mean uncorrected distant V.A. ± SD (decimal scale) Treated group 0.31 ± 0.11 0.44 ± 0.2
Control group 0.63 ± 0.09 0.42 ± 0.8
Mean corrected distant V.A. ± SD (decimal scale) Treated group 0.65 ± 0.11 0.66 ± 0.08
Control group 0.63 ± 0.09 0.65 ± 0.07
Mean spherical equivalent ± SD (D) Treated group 1.29 ± 0.83 0.94 ± 1.07
Control group 1.23 ± 0.91 1.87 ± 0.35
Mean astigmatism ± SD (D) Treated group 0.94 ± 0.53 0.86 ± 0.60
Control group 0.86 ± 0.66 0.85 ± 0.74
Mean intraocular pressure ± SD (mm Hg) Treated group 12.6 ± 1.9 9.0 ± 1.1
Control group 13.2 ± 1.8 12.6 ± 1.7
Mean corneal thickness ± SD (lm) Treated group 425.6 ± 19.8 429.6 ± 18.1
Control group 435.2 ± 17.6 432.3 ± 22.2
Mean corneal diopters ± SD (D) Treated group 37.2 ± 2.0 36.4 ± 1.4
Control group 36.9 ± 1.6 35.1 ± 1.8
D= diopters, V.A. = visual acuity, lm=micron, SD = standard deviation.
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Figure 2 CDVA before and 12 months after treatment.
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Figure 3 Spherical equivalent before and 12 months after
treatment.
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Figure 4 Astigmatism before and 12 months after treatment.
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Figure 5 IOP before and 12 months after treatment.
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Figure 6 Corneal thickness before and 12 months after
treatment.
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Figure 7 Corneal power before and 12 months after treatment.
84 H.E. El-Awady et al.decreased signiﬁcantly from 12.6 ± 1.9 to 9.0 ± 1.1 mm Hg
(P< 0.001) (Fig. 5). Mean corneal thickness did not change
signiﬁcantly from 425.6 ± 19.8 to 429.6 ± 18.1 lm (P=
0.73) (Fig. 6).
The mean refractive corneal power within 3 mm central
zone in diameter decreased signiﬁcantly from 37.2 ± 2.0 to
36.4 ± 1.4 diopters after 12 months treatment (P< 0.001)
(Fig. 7). No vision threatening complications were seen
throughout follow-up period.
At last follow-up, treated eyes with timolol 0.1% gel for
12 months reported 40 (80%) satisﬁed, 7 (14%) moderate sat-
isﬁed, and 3 (6%) dissatisﬁed. While, control eyes reported 30
(67%) satisﬁed, 10 (22%) moderate satisﬁed, and 5 (11%).
Dissatisﬁed patients in treated group complained of blurring
of vision (two eyes), and night glare (one eye).
Regarding the optical symptoms (glare, halos, double vi-
sion, and ghosting), treated eyes with timolol 0.1% gel for
Evaluation of the role of timolol 0.1% gel in myopic regression after laser in situ keratomileusis 8512 months reported an improvement from 8 (16%) to 2 (4%)
eyes, but no improvement reported in control eyes.5. Discussion
Although the exact mechanism for refractive regression re-
mains unclear, one of possible explanations for regression is
forward shift of the cornea. Steepening in the posterior surface
means an increase in the negative power of that surface. In
contrast, steepening in the anterior surface means an increase
in the positive refractive power. Considering that both surfaces
should bulge out equally, the anterior surface exerts far greater
absolute refractive changes than does the posterior surface, be-
cause the former faces the air and the latter is in contact with
the aqueous humor.
Accordingly, the forward shift of both surfaces counteracts
the refractive effects of surgery, implying that it can be one of
the factors responsible for refractive instability after excimer
laser surgery (Miyata et al., 2002). This is important when
enhancement ablation is required for myopic regression after
surgery. If corneal tissue is subtracted excessively from the
residual cornea, structural integrity of the cornea is compro-
mised further, resulting in greater forward shift and further
myopic regression (Kamiya and Oshika, 2003).
The once-daily application of timolol 0.1% gel in the
morning would be optimal for patient compliance, also have
another advantage since this would be expected to be associ-
ated with a lower plasma concentration of timolol at night.
The lower plasma concentration of timolol after timolol
0.1% gel administration means diminished nocturnal arterial
hypotension which in turn can lead to transient ischemia in
the optic nerve head, and demonstrated better systemic toler-
ance and safety with longer treatment period (Rouland et al.,
2002).
We demonstrated topical application of the timolol 0.1%
gel drug was effective in reducing the refractive regression,
especially of the spherical errors after LASIK. We also demon-
strated that eyes that gained the improvement of manifest
retraction of more than 0.25 and 0.5 diopters were 25
(26.3%) and 45 (47.3%) of 95 eyes, respectively. However, in
20 (21%) of 95 eyes, timolol 0.1% gel administration was
not effective, although there was some lowering effect of the
IOP in all eyes. Timolol 0.1% gel is a hydrogel formulation
which slowly liqueﬁes on ocular instillation and improving
subjective symptoms of dry eye.
Pan et al. (2004) demonstrated that regressive eyes and non-
regressive eyes exhibited similar time courses in central corneal
pachymetry, whereas they differed in the corneal shifting
movements after LASIK. These ﬁndings suggested that myo-
pic regression may be caused mainly by corneal protrusion
rather than by central corneal thickness, which is in good
agreement with the Gullatrand principle that changes in cor-
neal thickness play a subtle role in the total refraction of the
eye. We found that there were non-signiﬁcant changes in cor-
neal thickness before and after treatment, indicating that cor-
neal hydration may not play an important role in the refractive
changes in these eyes.
Baek et al. (2001) reported in a study of 196 eyes undergo-
ing LASIK that the higher IOP, the more it predisposes the
cornea to an anterior shift. Toshino et al. (2005) presented a
case of transient keratectasia in relation to marked elevationof 1OP after LASIK. In addition, Hiatt et al. (2005) described
a similar case of corneal ectasia that was reversed with 1OP
reduction. These previous ﬁndings indicate that a higher 1OP
may be one of the main causative factors for structurally com-
promised corneas after LASIK. Hence, we assumed that it may
be highly effective for regression mainly caused by corneal geo-
metrical changes.
Many cases of myopic regression may be caused unexpect-
edly by forward movement of the cornea, other factors such as
epithelial hyperplasia, development of new stromal collagen,
and nuclear sclerosis of the lens may play a signiﬁcant role
in myopic regression (Lohmann et al., 1999; Moller-Pedersen
et al., 2000).
We found that 1OP after 12 months of treatment with
timolol 0.1% gel was signiﬁcantly lower than the IOP before
treatment, as its ocular hypotensive efﬁcacy was approxi-
mately 7 mm Hg or a 26% reduction from a baseline. The
mean refractive power of the total cornea also decreased
signiﬁcantly after treatment. These results indicate that IOP
reduction may have induced a backward shift of the cornea
and reduction of corneal refractive power, resulting in refrac-
tive improvement in post-LASIK eyes. It may be that the
morphologic properties of the cornea are affected easily by
subtle changes in IOP and atmospheric pressure when corneal
rigidity is impaired by ﬂap manipulation and laser ablation
such as LASIK.
From a biomechanical point of view, Hiatt et al. (2005)
continued to use topical application of lOP-lowering eye
drops for 7 months when the cornea was believed to have
stabilized, but the recurrence occurred on topography at
10 months after treatment, indicating that biomechanical
remodeling of the cornea had not been completed even
10 months after application. However, Toshino et al. (2005)
reported that corneal ectasia did not recur on topography
after the normalization of IOP during a 12-month follow-
up. Because it is unclear when the biomechanical properties
of the cornea have stabilized, it is also unknown how long
this treatment needs to be continued. If the refractive effects
depend simply on the degree of IOP reduction, the patients
may be required to use the antiglaucoma drugs continuously.
Long-term results after cessation of the medication would
help to strengthen the case for the use of antiglaucoma med-
ication in these patients.
Until now, enhancement ablation has been the sole treat-
ment for the correction of residual refractive error after exci-
mer laser surgery. The current approach is unique in simply
taking lOP-lowering eye drops, and thus it is clinically applica-
ble to regressive eyes after refractive surgery. Moreover, it has
advantages over enhancement ablation because it seems to be
less invasive and to cause fewer side effects (e.g., keratectasia)
in light of the biomechanical stability of the cornea. Although
the refractive effect of this treatment is mild (approximately
0.5 diopters), we ﬁrst could attempt this new treatment before
considering enhancement surgery, especially when the amount
of myopic regression is not very large.
In conclusion, we demonstrated that topical application of
the lOP lowering drug is effective for the correction of the
refractive regression that presumably results from the back-
ward movement of the cornea and the ﬂattening of its curva-
ture after LASIK. This new approach to regression may be
capable of improving refractive outcomes after keratorefrac-
tive surgery.
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